Latest Impairment News

EROAD Limited reported stable FY26 revenue of NZD 195 million amid a $134.7 million North American impairment, unveiling a strategic reset centred on ANZ growth and its expanding electronic Road User Charges platform.

LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.

Reliance Worldwide Corporation plans to shutter its brass manufacturing in Melbourne, citing declining volumes tied to automation and supply chain shifts, while targeting a US$9 million boost to operating earnings by FY27.

Vection Technologies has locked in approximately $2.3 million in new AI-related contracts spanning healthcare, luxury fashion, public services, airport passenger assistance, and security, pushing total orders since April 2026 to around $7 million.

General Capital Limited posted record revenue growth of 18% to $26.76 million for FY26, driven by a 63% jump in loan receivables and a 34% rise in term deposits. The group declared a final dividend, reflecting confidence amid economic uncertainty and a positive credit rating upgrade for its finance subsidiary.

EQT Holdings is stepping away from its superannuation trustee arm to sharpen focus on core corporate and wealth services, triggering a $13 million impairment and legal expenses in FY26.

Peak Processing has reported three consecutive months of positive EBITDA and raised its Q4 FY26 beverage production guidance to approximately 1.6 million units, surpassing earlier estimates.

Frasers Group has initiated an unconditional on-market takeover bid for Accent Group at $0.65 per share, aiming to increase its stake beyond 22.9% amid concerns over Accent’s recent financial performance and strategic direction.

Green Cross Health Limited reported a 28% rise in net profit to NZD 20.4 million for FY26, driven by gains in both pharmacy and medical divisions. The company announced a conditional sale of its Medical division to Tend Health for NZD 270 million, aiming to refocus on its core pharmacy business.

MGX Resources is set to exit its Koolan Island iron ore operation, selling to Crestlink for $20.2 million upfront plus potential revenue share, while shifting focus to gold development.

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

Lithium Universe (ASX: LU7) has launched a detailed development program to commercialise a novel hydrometallurgical process for extracting gold and copper from electronic waste, aiming to disrupt traditional smelting with a more sustainable, low-energy method.